Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials

Table 1 Characteristics of randomized controlled trials of ramosetron vs placebo in irritable bowel syndrome with diarrhea

Study	Country	Criteria for IBS	Sample size (ramosetron vs placebo)	Dose	Treatment duration	Follow-up duration	Primary outcomes	Secondary outcomes
Matsueda K 2008a [25]	Japan	Rome II	270 vs 269	5 μg	12 weeks	12 weeks	Relief of overall IBS symptoms	1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptoms^a
Matsueda K 2008b [26]	Japan	Rome II	103 vs 109	5 μg	12 weeks	12 weeks	Relief of overall IBS symptoms	1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptoms^a
Fukudo S 2014 [22]	Japan	Rome III	147 vs 149	5 μg	12 weeks	12 weeks	Improvement in stool consistency	1.Relief of overall IBS symptoms 2.Relief of abdominal discomfort/pain 3.Improvement in abnormal bowel habits 4.Assessment of IBS symptoms^a 5.IBS-QOL
Fukudo S 2015 [23]	Japan	Rome III	292 vs 284	2.5 μg	12 weeks	12 weeks	1.Relief of overall IBS symptoms 2.Improvement in stool consistency	1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptoms^a 4.IBS-QOL

IBS-QOL, irritable bowel syndrome-quality of life
^aAssessment of IBS symptoms included severity of abdominal discomfort and/or pain, stool form, stool frequency, urgency and feeling of incomplete bowel movement